prothymosin alpha raises a handful of sensible questions. This page answers them in order, starting with the fundamentals and moving to applications.
This page was last updated on 2025-09-23 and is reviewed periodically as new material appears.
Thymosin alpha 1 was identified in 1977 as a component of thymosin fraction 5, a heterogeneous preparation used in early studies of thymic function. Investigators purified the active material and determined its amino acid sequence, which enabled chemical synthesis. Work in the following decades concentrated on T-cell maturation and immune reconstitution in animals and small human cohorts. Early preparations varied in composition, so results from that period are difficult to compare with studies using defined synthetic peptide.
Clinical research has examined the peptide in chronic hepatitis B and C, as a vaccine adjuvant, and in sepsis and oncology settings. Findings across trials are mixed; some report changes in selected immune markers, while others find no clear clinical benefit. Many studies are small and define outcomes differently, which limits comparison. Regulatory approval is confined to a few countries, and the compound is not an approved drug in the United States or most of Europe.
Stability depends on temperature, pH, and the number of freeze-thaw events the sample has experienced. Freeze-dried material is commonly held at -20 °C or colder, while reconstituted liquid is kept cold and used within a short window. Extreme pH and prolonged light exposure can promote deamidation, oxidation, or aggregation, particularly at asparagine and methionine positions. Adsorption to container walls can lower the measured concentration of a dilute solution even when the peptide molecules themselves remain intact.
Identity and purity are usually assessed by reversed-phase high-performance liquid chromatography, which separates the target peptide from truncated or chemically modified byproducts. Mass spectrometry confirms the expected molecular mass and can indicate acetylation state or sequence errors. Amino acid analysis and peptide mapping supply complementary sequence-level information, while endotoxin testing is relevant for preparations intended for cell or animal work. Purity figures reported by suppliers refer to the method used and are not directly comparable across laboratories unless conditions are stated.
Lyophilized material is typically treated as a hygroscopic solid that should be brought to room temperature before the container is opened, which limits condensation on the powder. Reconstitution is commonly done with sterile water or a buffered diluent, and gentle mixing is preferred over vigorous agitation to reduce foaming and surface adsorption. Because peptides can bind to plastic and glass, diluents containing a small amount of carrier protein are sometimes used in laboratory work. Working solutions are generally aliquoted and prepared fresh rather than subjected to repeated freezing and thawing.
| Property | Value | Notes |
|---|---|---|
| First described | 1977 | Reported as a component of thymosin fraction 5 |
| Sequence length | 28 amino acids | N-terminal residue is acetylated |
| Net charge at neutral pH | Negative | Reflects a high proportion of acidic residues |
| Principal studied uses | Chronic hepatitis B and vaccine adjuvant | Research uses outnumber approved indications |
| Regulatory status | Approved in a limited number of countries | Not approved in the United States or most of Europe |
The peptide is generated in cells by cleavage of prothymosin alpha, a larger acidic protein encoded by the PTMA gene. Prothymosin alpha is expressed in many tissues, not only in the thymus, and its functions include nuclear roles in chromatin-related processes. The 28-residue fragment corresponds to the N-terminal portion of that precursor. How the cleavage occurs and how the fragment's concentration is regulated remain open questions; circulating amounts are small and difficult to measure reliably with routine assays.
Thymosin alpha 1 is a short peptide first isolated from bovine thymus tissue in the early 1970s during fractionation work aimed at identifying factors that influence T cell development. It belongs to a family of acidic thymic peptides, and the original preparations contained several components that were later separated by chromatography. The compound is now produced synthetically rather than extracted from tissue, which removes batch variability tied to animal sourcing. Researchers describe it as an immunomodulatory peptide because laboratory studies show effects on several cell types of the innate and adaptive immune systems.
The molecule consists of 28 amino acid residues with an acetyl group attached to the N-terminal serine. Its sequence is acidic overall, with several glutamic and aspartic acid residues distributed along the chain and no cysteine, so disulfide bridges do not form. The peptide carries a net negative charge at physiological pH. Because the N-terminus is blocked, the intact molecule resists degradation by many aminopeptidases, which contributes to its stability in biological fluids.
The peptide was identified during work in the 1970s on thymosin fraction 5, a partially purified extract of calf thymus. Investigators separated that mixture and characterized individual components, one of which they named thymosin alpha-1. The same compound later received the international nonproprietary name thymalfasin. Commercial material is produced by solid-phase peptide synthesis rather than by extraction, so synthetic and natural forms share an identical sequence. Naming conventions vary across the literature, and readers should distinguish the alpha-1 peptide from other thymosins that have unrelated sequences and functions.
Thymosin beta-4 is a separate 43-residue peptide that binds actin and participates in cell migration; it shares no sequence similarity with thymosin alpha-1 despite the common family name. Other preparative materials, such as thymosin fraction 5 and thymopoietin, contain distinct mixtures or peptides. The shared thymosin label reflects the tissue of origin used in early purification, not a common structural core. Treating these molecules as interchangeable is a frequent source of confusion in laboratory reports and in popular summaries alike.
Thymosin alpha-1 is a synthetic peptide of 28 amino acids whose sequence matches the amino-terminal region of prothymosin alpha. The chain is acetylated at its first residue and contains one disulfide bridge between two cysteine residues, which folds the molecule into a compact loop. Its molecular formula, C129H215N33O55, corresponds to a monoisotopic mass of roughly 3,106 daltons. Material used in laboratories is made by solid-phase synthesis rather than isolated from animal tissue.
Early work on thymic extracts in the 1960s described a heat-stable acidic fraction containing many polypeptides. Separation of that mixture yielded individual components, and thymosin alpha-1 was named as one of them on the basis of assays for T-cell activity. The first preparations came from calf thymus, while subsequent research and clinical material has been chemically synthesized. Nomenclature in older papers is inconsistent, and the same peptide sometimes appears under different designations, which complicates literature searches.
Within the immune system, the peptide acts on several cell types rather than a single target. Reported activities include promotion of T-cell maturation, enhancement of natural killer cell activity, and modulation of cytokine production by dendritic cells and macrophages. Some of these effects appear to operate through toll-like receptor signaling, though the precise receptor-level mechanism remains debated. Whether the observed immune changes translate into clinical benefit is a separate question and depends on the indication studied.
The peptide was described in the 1970s as a component of thymic extracts, and early research focused on restoring immune function in immunodeficiency states. A synthetic version entered clinical development in the 1980s and is approved as a drug in several countries for conditions such as chronic hepatitis B and certain immunodeficiencies. Approval status varies widely by jurisdiction, and in the United States it is not an approved therapeutic. Regulatory and clinical positions differ, so statements about efficacy should be tied to specific indications and studies.
Thymosin alpha-1 is a synthetic peptide of 28 amino acids, corresponding to the N-terminal fragment of prothymosin alpha. Its sequence begins with acetylation at the N-terminus, a modification that affects stability and receptor interaction. The peptide is acidic, with a calculated isoelectric point near 4.2, and carries no disulfide bonds, so its secondary structure is largely flexible in solution. Molecular mass is approximately 3108 daltons. The native form was first isolated from bovine thymus tissue, while pharmaceutical material is produced by solid-phase peptide synthesis.
Pyridoxal phosphate (PLP, pyridoxal 5'-phosphate, P5P, scientitifically known as 4-formyl-5-hydroxy-6-methylpyridin-3-yl)methyl dihydrogen phosphate, the active form of vitamin B6, is a coenzyme in a variety of enzymatic reactions. The International Union of Biochemistry and Molecular Biology has catalogued more than 140 PLP-dependent activities, corresponding to ~4% of all classified activities. The versatility of PLP arises from its ability to covalently bind the substrate, and then to act as an electrophilic catalyst, thereby stabilizing different types of carbanionic reaction intermediates.
is the spatial velocity gradient tensor. If only these two original criteria are used to define hypoelasticity, then hyperelasticity would be included as a special case, which prompts some constitutive modelers to append a third criterion that specifically requires a hypoelastic model to not be hyperelastic (i.e., hypoelasticity implies that stress is not derivable from an energy potential). If this third criterion is adopted, it follows that a hypoelastic material might admit nonconservative adiabatic loading paths that start and end with the same deformation gradient but do not start and end at the same internal energy. Note that the second criterion requires only that the function
=== Live insect feed === Other insects not killed by farming companies are sold live for consumption by fish and pets. 95% of the Kreca company's insects are sold live. Of the 1500 kg per week of mealworms produced by the Van de Ven company, most are sold as live feed. Live insects may be required for some pets that will not consume dead prey. For instance, monitor lizards are typically fed live insects and may not eat pre-killed ones. It is generally hard to convert reptiles and amphibians that eat insects to pre-killed prey, though some pet owners can feed dead insects by moving or dangling them. For instance, bearded dragons can be fed dead crickets by hiding them in other food, dangling them with tongs, squirting them with water, or vibrating a bowl. Pet spiders, or praying mantids and other insectivorous bugs, typically require live food. Live insects may also be commonly used as fishing bait, with the result that they are either eaten alive by fish or drowned.
=== Urinary glucose testing === Women with GDM may have high glucose levels in their urine (glucosuria). Although dipstick testing is widely practiced, it performs poorly, and discontinuing routine dipstick testing has not been shown to cause underdiagnosis where universal screening is performed. Increased glomerular filtration rates during pregnancy contribute to some 50% of women having glucose in their urine on dipstick tests at some point during their pregnancy. Glomerular filtration rates increase during pregnancy due to an increase in blood volume to support the fetus. The sensitivity of glucosuria for GDM in the first two trimesters is only around 10%, and the positive predictive value is around 20%.
Sources: en.wikipedia.org
=== ColdFusion 4 === Released in Nov 1998, version 4 is when the name was changed from "Cold Fusion" to "ColdFusion" - possibly to distinguish it from Cold fusion theory. The release also added the initial implementation of cfscript, support for locking (cflock), transactions (cftransaction), hierarchical exception handling (cftry/cfcatch), sandbox security, as well as many new tags and functions, including cfstoredproc, cfcache, cfswitch, and more.
=== Frazier === On September 29, 2025, Seth Frazier, then 41 years old, pleaded guilty to four counts of first degree murder, one count of attempted first degree murder, six counts of assault with a deadly weapon with the intent to kill inflicting serious injury, and one count each of burning a public building, inciting riot, attempting escape and assault with a deadly weapon. As a result of his plea of guilt, Frazier was spared the death sentence and instead sentenced to four consecutive life sentences without parole for all four murder charges, plus 93 to 116 years for all the lesser offences he admitted to. Similarly to his co-defendants, Frazier was transferred into the federal prison system and is currently at USP Terre Haute.
Christian – 76.7% (19,567 people) Muslim – 1.4% (363 people) Jewish – 0.7% (182 people) Hindu – 0.7% (168 people) Buddhist – 0.4% (94 people) Sikh – 0.2% (39 people) Any other religion – 0.2% (58 people) No religion – 13.3% (3,390 people) Religion not stated – 6.1% (1,555 people).
The original Counter-Strike has been played in competitive tournaments since 2000, with the first major event taking place at the Cyberathlete Professional League (CPL) Winter Championship in 2001. The CPL announced a transition from Quake III Arena to Counter-Strike for the Winter Championship. Prior to this, the 2000 Babbage's event featured a Counter-Strike competition sponsored by Kärna, the parent company of Razer, offering a $15,000 prize pool. However, Kärna experienced financial difficulties, leading to delays in prize payouts. On March 14, 2001, the CPL issued a statement confirming that alternative arrangements would be made if the payments were not received by April 2, 2001.
Growth hormone secretagogue receptor(GHS-R), also known as ghrelin receptor, is a G protein-coupled receptor that binds growth hormone secretagogues (GHSs), such as ghrelin, the "hunger hormone". The role of GHS-R is thought to be in regulating energy homeostasis and body weight. In the brain, they are most highly expressed in the hypothalamus, specifically the ventromedial nucleus and arcuate nucleus. GSH-Rs are also expressed in other areas of the brain, including the ventral tegmental area, hippocampus, and substantia nigra. Outside the central nervous system, too, GHS-Rs are also found in the liver, in skeletal muscle, and even in the heart.
Sources: en.wikipedia.org
In FFF the display of detector signals as a function of time is called fractogram, in contrast to the chromatogram of column chromatography techniques. The fractogram can be converted to a distribution plot of one or several physical properties of the analyte using FFF theory and/or detector signals. This can be size, molar mass, charge, etc. Often these substances are particles initially suspended in a small volume of a liquid buffer and pushed along the FFF channel by the buffer. The varying velocities of a particular species of particles may be due to its size, its mass, and/or its distance from the walls of a channel with non-uniform flow-velocity. The presence of different species in a sample can thus be identified through detection of a common property at some distance down the long channel, and by the resulting fractogram indicating the presence of the various species by peaks, due to the different times of arrival characteristic of each species and its physical and chemical properties.
== Clinical significance == Tumorigenesis in mammary glands can be induced biochemically by abnormal expression level of circulating hormones or local ECM components, or from a mechanical change in the tension of mammary stroma. Under either of the two circumstances, mammary epithelial cells would grow out of control and eventually result in cancer. Almost all instances of breast cancer originate in the lobules or ducts of the mammary glands.
=== Discovery, regulation and marketing === Docetaxel is marketed worldwide under the name Taxotere by Sanofi-Aventis as well as Docefrez by Sun Pharma Global and Zytax by Zydus. Annual sales of Taxotere in 2010 were €2.122 billion (US$3.1 billion). The patent expired in 2010. Docetaxel was developed by Rhône-Poulenc Rorer (now Sanofi-Aventis) following from the discoveries of Pierre Potier at CNRS at Gif-sur-Yvette during his work on improvements to the production of paclitaxel (Taxol) using the local European yew.
Charles Miller Metzner (1931), judge on the United States District Court for the Southern District of New York and the Temporary Emergency Court of Appeals Lawrence E. Walsh (1932), independent counsel in the Iran-Contra affair; 4th United States Deputy Attorney General William Golub (1934), lawyer and advisor to Governor Nelson Rockefeller Harold Leventhal (1934), judge on the United States Court of Appeals for the District of Columbia Circuit John Slate (1935), lawyer and name partner of Skadden Arps Slate Meagher & Flom Daniel Mortimer Friedman (1937), judge of the United States Court of Appeals for the Federal Circuit, last chief judge of the United States Court of Claims, and acting solicitor general of the United States Wilfred Feinberg (1940), judge of the United States Court of Appeals for the Second Circuit Hugh H. Bownes (1941), judge of the United States Court of Appeals for the First Circuit Richard Kuh (1941), New York County district attorney and prosecutor of Lenny Bruce for obscenity Leonard I. Garth (1942), senior judge on the United States Court of Appeals for the Third Circuit Charles L. Brieant (1944), judge of the United States District Court for the Southern District of New York Jack Greenberg (1945), civil rights lawyer who argued the Brown v. Board of Education case before the United States Supreme Court Roy Cohn (1946), attorney and counsel to Sen. Joseph McCarthy Arthur Lazarus Jr. (1947), American Indian rights lawyer, argued United States v.
Sources: en.wikipedia.org
Trials differ in patient population, dose schedule, background treatment, and the endpoints used to judge success. Many are small and single-center, so random variation can dominate the reported effects.
Authorization is limited to a small number of countries and covers specific indications such as chronic hepatitis B and vaccine adjuvant use. Availability and labelling differ by jurisdiction.
Most reviews describe it as an immunomodulatory agent with an uncertain clinical effect. They generally call for larger, better-controlled trials before firm conclusions are drawn.
Cold storage slows the chemical degradation reactions that occur in solution. Lyophilized powder is more stable than reconstituted liquid and tolerates longer storage periods. Repeated temperature cycling should still be avoided because it can drive aggregation and loss of material.